Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharma CS (NQ: ZYNE )

3.580 USD UNCHANGED
Official Closing Price Updated: 7:47 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Zynerba Pharma CS

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
From GlobeNewswire News Releases
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary 
From Business Wire News Releases
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. (ZYNE) 
From Business Wire News Releases
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or the “Company”) (NASDAQ: ZYNE) concerning whether the board... 
From Business Wire News Releases
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th An
From GlobeNewswire News Releases
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Co
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting
From GlobeNewswire News Releases
Legalization Efforts Continue to Drive the Cannabis Market Growth
FinancialBuzz.com News Commentary 
From PR Newswire
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Provides Update on Recent Milestones
From GlobeNewswire News Releases
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
More People Turn to CBD as its List of Applications Grows
FinancialBuzz.com News Commentary 
From PR Newswire
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
From GlobeNewswire News Releases
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
From GlobeNewswire News Releases
Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup
- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - 
From GlobeNewswire News Releases
Psychedelic Compounds Could be Used in Mental Healthcare
FinancialBuzz.com News Commentary 
From PR Newswire
Regulators Move to Remove Restriction on Some Uses of Psilocybin
FinancialBuzz.com News Commentary 
From PR Newswire
Thinking about buying stock in YRC Worldwide, Zynerba Pharmaceuticals, Workhorse Group, Vaxart Inc, or United Airlines?
InvestorsObserver issues critical PriceWatch Alerts for YRCW, ZYNE, WKHS, VXRT, and UAL. 
From PR Newswire
Thinking about buying stock in Zomedica Pharmaceuticals, Nio Inc, Advanced Micro Devices, Norwegian Cruise Line, or Zynerba Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for ZOM, NIO, AMD, NCLH, and ZYNE. 
From PR Newswire
Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome
From GlobeNewswire News Releases
Therapeutic Use of CBD Continues to Spread
FinancialBuzz.com News Commentary 
From PR Newswire
Psychedelics Represent a New Frontier for Mental Healthcare
FinancialBuzz.com News Commentary 
From PR Newswire
Studies Into Psychedelic Drugs Reveal Significant Medical Potential
FinancialBuzz.com News Commentary 
From PR Newswire
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
From GlobeNewswire News Releases
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtu
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.